![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
North Suffolk Mental Health Association |
Information provided by: | North Suffolk Mental Health Association |
ClinicalTrials.gov Identifier: | NCT00573300 |
In this pilot study, we propose to characterize the pattern of activation of the kynurenine pathway of tryptophan metabolism in peripheral macrophages of patients with schizophrenia. To do this, we will measure the gene expression of several major enzymes in this pathway in macrophages, including the key enzyme involved in tryptophan to kynurenine metabolism, IDO, by means of quantitative reverse-transcription polymerase chain reaction (RT-PCR). The focus on enzyme mRNA expression as opposed to serum or cerebrospinal fluid levels of metabolites provides a possibly more sensitive characterization of the activation of this metabolic pathway.
Condition | Intervention |
Schizophrenia |
Procedure: Phlebotomy |
MedlinePlus related topics: | Schizophrenia |
Drug Information available for: | Tryptophan |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative RT-PCR Study |
Whole blood
Estimated Enrollment: | 60 |
Study Start Date: | January 2006 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
Schizophrenia
Schizophrenia Patients
|
Procedure: Phlebotomy
Single blood draw
|
Healthy Controls
Healthy Controls
|
Procedure: Phlebotomy
Single blood draw
|
In this pilot study, we propose to characterize the pattern of activation of the kynurenine pathway of tryptophan metabolism in peripheral macrophages of patients with schizophrenia. To do this, we will measure the gene expression of several major enzymes in this pathway in macrophages, including the key enzyme involved in tryptophan to kynurenine metabolism, IDO, by means of quantitative reverse-transcription polymerase chain reaction (RT-PCR). The focus on enzyme mRNA expression as opposed to serum or cerebrospinal fluid levels of metabolites provides a possibly more sensitive characterization of the activation of this metabolic pathway.
Primary hypotheses: We hypothesize that patients with schizophrenia will differ in their expression of macrophage IDO mRNA, reflecting activation of this pathway compared to normals. We further hypothesize that patients with deficit syndrome will have higher degrees of enzyme activation.
Secondary hypotheses: Serum tryptophan levels will be lower in patients with schizophrenia compared to controls, and they will correlate with measures of dysphoria. Serum kynurenine levels will be elevated in patients with schizophrenia, particularly in deficit syndrome patients. mRNA expression levels of enzymes downstream from IDO will differ between patients and controls. Measures of immune activation will be influenced by medical disease burden (medical comorbidities).
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Schizophrenia patients
Inclusion Criteria:
Contact: Jared P Walsh, BA | 617-912-7864 | jpwalsh@partners.org |
United States, Massachusetts | |||||
Freedom Trail Clinic | Recruiting | ||||
Boston, Massachusetts, United States, 02114 | |||||
Contact: Jared P Walsh, BA 617-912-7864 jpwalsh@partners.org | |||||
Principal Investigator: Oliver Freudenreich, M.D. | |||||
Sub-Investigator: Donald C Goff, M.D. | |||||
Sub-Investigator: David C Henderson, M.D. | |||||
Sub-Investigator: Mark Brockman, PhD |
North Suffolk Mental Health Association |
Principal Investigator: | Oliver Freudenreich, M.D. | North Suffolk Mental Health Association |
Responsible Party: | Massachusetts General Hospital ( Oliver Freudenreich, MD ) |
Study ID Numbers: | CORRC#10-2005 |
First Received: | December 13, 2007 |
Last Updated: | June 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00573300 |
Health Authority: | United States: Institutional Review Board |
|
|
|
![]() |